A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

A new mRNA vaccine against tuberculosis (TB) is showing favorable results in preclinical trials. With only one currently ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials ...

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...

Humans have been selectively breeding cats and dogs for thousands of years to make more desirable pets. A new startup called ...

The Recombinant DNA Technology Market size is expected to be worth around USD 1288.5 Bn by 2032 from USD 786.7 Bn in 2023, growing at a CAGR of 5.8% As scientific and technological advancements ...

A lot of people are staunchly pro-vaccines, some are militant anti-vaxxers and much of the population is wondering what all the fuss is about. If you already have a firm viewpoint on the question of ...

the partners said they also plan to develop next-generation saRNA-based vaccines for both human and animal health. Under the partners’ current strategy, the production platform will wed DNA ...

Microbiota-targeted interventions have the potential to complement effectiveness of COVID-19 vaccines. Data are available in a public, open access repository. Quality-controlled and human DNA-removed ...

Briefly, the DNA fragment encoding the S-ECD (amino acids 1 to ... To prepare the S protein subunit vaccine, the purified recombinant S protein was mixed in a 1:1 (w/w) ratio with MONTANIDE™ ISA 201 ...